The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.
National Institutes of Health
Investigational AstraZeneca vaccine prevents COVID-19
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization. The independent Data and Safety Monitoring Board (DSMB) overseeing the trial identified no safety concerns related to the vaccine. The United Kingdom-based global biopharmaceutical company AstraZeneca developed the vaccine and led the trial as regulatory sponsor.
Preterm birth, prolonged labor influenced by progesterone balance
New research by the National Institutes of Health found that unbalanced progesterone signals may cause some pregnant women to experience preterm labor or prolonged labor. The study in mice — published online in the Proceedings of the National Academy of Sciences — provides novel insights for developing treatments.
NIH invests in next iteration of public-private partnership to advance precision medicine research for Alzheimer’s disease
The National Institutes of Health has launched the next version of the Accelerating Medicines Partnership (AMP) Alzheimer’s disease program (AMP AD 2.0) to expand the open science, big data approach for identifying biological targets for therapeutic intervention.
New experiences enhance learning by resetting key brain circuit
Changes in brain activity throughout training revealed the neuronal mechanisms that drive this novelty-enhanced learning.
NIH funds study to evaluate remdesivir for COVID-19 in pregnancy
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who have been prescribed the drug to treat COVID-19. The study, which will be conducted at 17 sites in the continental United States and Puerto Rico, aims to determine how pregnant women metabolize the drug and whether there are any potential side effects.
Combination treatment for common glioma type shows promise in mice
In a study funded by the National Institutes of Health, researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas — a type of slow-growing glioma—and found tumor regression in 60 percent of the mice treated. These encouraging results, published in the Journal of Clinical Investigation, could be the first step toward developing a treatment for this type of brain cancer.
Specimen-news.com 